Core Viewpoint - The stock of Fuhong Hanlin (02696) rose nearly 5% in early trading, reflecting positive market sentiment following recent developments in clinical research and regulatory approvals [1] Group 1: Clinical Research Developments - Fuhong Hanlin successfully held an offline investigator meeting in San Francisco for the HLX22-GC-301 study, focusing on the international multicenter Phase III clinical trial of the anti-HER2 monoclonal antibody HLX22 in combination with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer [1] - The company announced the approval from the National Medical Products Administration for clinical trials of HLX43 in combination with HLX07 and surufatinib for the treatment of advanced solid tumors, with plans to initiate a Phase II clinical study in China once conditions are met [1] Group 2: Market Performance - As of the report, Fuhong Hanlin's stock was trading at 58.4 HKD, with a trading volume of 19.16 million HKD, indicating strong investor interest [1]
港股异动 | 复宏汉霖(02696)早盘涨近5% HLX22头对头K药胃癌III期临床美国研究者会顺利举行